MyoKardia

MyoKardia is committed to revolutionizing the treatment of cardiovascular diseases. The company's first projects include hypertrophic and dilated cardiomyopathy (HCM and DCM), which together afflict approximately 1 million people in the United States, and for which no new therapies have been introduced to the market in over a decade.Mavacamten, a drug under MyoKardia, is a potential first-in-class cardiovascular drug for the treatment of hypertrophic obstructive cardiomyopathy (HCM), a chronic heart disease with high morbidity and significant patient impact.